Nicola J Mason

faculty photo
Associate Professor of Medicine & Pathobiology, University of Pennsylvania School of Veterinary Medicine

Contact information
Room 315, Hill Pavilion
380, South University Avenue
Philadelphia, PA 19104-6160
Office: 215 898 3996
Fax: 215 746 2995
Graduate Group Affiliations
Education:
BVetMed (Veterinary Medicine )
University of London , 1992.
PhD (Immunology)
University of Pennsylvania , 2004.
Permanent link
 

Description of Research Expertise

Dr. Mason’s lab focuses on developing novel approaches to generate functional, tumor-specific cytotoxic T lymphocytes. One approach involves active immunization using whole tumor RNA loaded CD40 activated B cells, aimed at activating tumor specific T cells in vivo. A second approach involves the passive adoptive transfer of genetically modified autologous T cells that are capable of MHC-independent tumor antigen recognition and activaton/effector function in the absence of co-stimulatory ligands. A second related focus of Dr. Mason’s lab is to identify novel tumor-associated antigens and to develop single-chain Fragment variable targeting systems that can be used alone or in concert with cell based therapies to target spontaneous occurring tumors. Through innovative clinical trials in canine cancer patients, the lab is working in concert with clinical oncologists to evaluate the safety and efficacy of both active immunization and passive adoptive transfer of genetically modified T cells in the treatment of spontaneously occurring cancer.

Description of Itmat Expertise

Dr. Mason focuses on the translation of basic scientific immunological principles that govern the generation of adaptive immune responses into therapeutically relevant hypotheses that can be tested for safety and therapeutic efficacy in canine patients with spontaneously occurring disease.

Selected Publications

Panjwani M Kazim, Smith Jenessa B, Schutsky Keith, Gnanandarajah Josephine, O'Connor Colleen M, Powell Daniel J, Mason Nicola J: Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Molecular therapy : the journal of the American Society of Gene Therapy 24(9): 1602-14, Sep 2016.

Mason Nicola J, Gnanandarajah Josephine S, Engiles Julie B, Gray Falon, Laughlin Danielle, Gaurnier-Hausser Anita, Wallecha Anu, Huebner Margie, Paterson Yvonne: Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research 22(17): 4380-90, Sep 2016.

Habineza Ndikuyeze Georges, Gaurnier-Hausser Anita, Patel Reema, Baldwin Albert S, May Michael J, Flood Patrick, Krick Erika, Propert Kathleen J, Mason Nicola J: A Phase I Clinical Trial of Systemically Delivered NEMO Binding Domain Peptide in Dogs with Spontaneous Activated B-Cell like Diffuse Large B-Cell Lymphoma. PloS one 9(5): e95404, 2014.

Callan Mary Beth, Werner Petra, Mason Nicola J, Meny Geralyn M, Raducha Michael G, Henthorn Paula S: Polymorphisms in canine platelet glycoproteins identify potential platelet antigens. Comparative medicine 63(4): 348-54, Aug 2013.

Huang Shih-Hung, Kozak Philip J, Kim Jessica, Habineza-Ndikuyeze Georges, Meade Charles, Gaurnier-Hausser Anita, Patel Reema, Robertson Erle, Mason Nicola J: Evidence of an oncogenic gammaherpesvirus in domestic dogs. Virology Mar 2012.

Ito Daisuke, Frantz Aric M, Williams Christina, Thomas Rachael, Burnett Robert C, Avery Anne C, Breen Matthew, Mason Nicola J, O'Brien Timothy D, Modiano Jaime F: CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leukemia & lymphoma Feb 2012.

Braganza Andrea, Wallace Koranda, Pell Laura, Parrish Colin R, Siegel Don L, Mason Nicola J: Generation and validation of canine single chain variable fragment phage display libraries. Veterinary immunology and immunopathology 139(1): 27-40, Jan 2011.

Ahern Benjamin J, Schaer Thomas P, Terkhorn Shawn P, Jackson Karen V, Mason Nicola J, Hankenson Kurt D: Evaluation of equine peripheral blood apheresis product, bone marrow, and adipose tissue as sources of mesenchymal stem cells and their differentation potential. American journal of veterinary research 72(1): 127-33, Jan 2011.

Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ.: CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLOS One 6(8): e24167, 2011.

Gaurnier-Hausser A, Patel R, Baldwin AS, May MJ, Mason N.: NEMO Binding Domain peptide inhibits constitutive NF-{kappa}B activity and reduces tumor burden in a canine model of relapsed, refractory Diffuse Large B-Cell Lymphom. Clin Cancer Res. Month 2011.

back to top
Last updated: 09/08/2017
The Trustees of the University of Pennsylvania